Status:
COMPLETED
A Study of Aripiprazole in Patients With Major Depressive Disorder
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label market...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and women, 18-65 years old who have experienced single or recurrent, non-psychotic episodes of Major Depressive Disorder, with the current episode of minimally 8 weeks in duration.
- Treatment history of an inadequate response to at least one and no more than three adequate antidepressant trials.
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
349 Patients enrolled
Trial Details
Trial ID
NCT00105196
Start Date
March 1 2005
End Date
March 1 2008
Last Update
December 2 2013
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Alabama At Birmingham
Birmingham, Alabama, United States, 35205
2
Sharp Mesa Vista Hospital
San Diego, California, United States, 92123
3
George Washington University Medical Center
Washington D.C., District of Columbia, United States, 20037
4
Cns Clinical Research Group
Coral Springs, Florida, United States, 33065